uniQure N.V. — Form 8-K
Filed September 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
uniQure announced submission of a Biologics License Application (BLA) to the FDA for ifezuntirgene inilparvovec (AMT-130) for Huntington's disease treatment, supported by three-year Phase I/II data showing slowed disease progression. The company also submitted a Marketing Authorisation Application (MAA) to the U.K. MHRA and requested priority FDA review (potential 6-month review cycle). The product holds Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Fast Track designations from the FDA.
Why this rating
Regulatory submission of lead program for rare disease with no approved therapies; potential accelerated pathway. Material milestone but outcome uncertain; approval not guaranteed; success could substantially expand pipeline and revenue.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $49.77 ▲ 3.99% | at our read · unknown $47.86 | +10 min · unknown $47.86 ▲ 0.00% | +30 min · unknown $47.86 ▲ 0.00% | +1 hr · unknown $47.86 ▲ 0.00% | +4 hrs pending |
The stock had already moved -3.84% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.